StreetAlpha.app
Home › Stocks › EMBC

Embecta Corp. (EMBC)

Healthcare
$6.15
▼ −1.60%
LAST CLOSE · NOV 17

Embecta makes pen needles, insulin syringes and safety injection devices for people with diabetes. It last closed at $6.15 on Nov 17, down 1.60% on the day. EMBC reports earnings on Tue, Nov 24, 2026.

AI Auto Pilots
Is EMBC in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.0B
−7.6% vs a year ago
Net income
$87.5M
+4.7% vs a year ago
EPS (diluted)
$1.47
+3.5% vs a year ago
Free cash flow
$164.6M
16.2% margin
Valuation
Market cap
$348.5M
56.7M shares
P/E
4.2
Price over 12 month EPS
Price to sales
0.3
Market cap over revenue
Dividend yield
7.48%
$0.46 a share over 12 months
Balance sheet
Cash & equivalents
$214.7M
At Jun 30
Debt
$1.5B
At Jun 30
Shareholder equity
−$612.7M
Shares outstanding
56.7M
At Jul 31
Fiscal year endsSeptember
ExchangeNasdaq
Financials history
FY2021: $1.2B$1.2BFY2021FY2022: $1.1B$1.1BFY2022FY2023: $1.1B$1.1BFY2023FY2024: $1.1B$1.1BFY2024FY2025: $1.1B$1.1BFY2025

From EMBC's SEC filings, latest 10-Q for the period ending Jun 30, 2026 (filed Aug 7). Last 12 months adds up the four latest quarters.

Next report
Nov 24
2026 · Time not announced
Consensus EPS forecast
$0.31
$267.4M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated EMBC in the past 90 days.
Average 12-month target
No price targets on EMBC in the past 90 days.
Latest rating changes
B of A SecuritiesMaintained
May 18Sell$3
DateFirmActionRatingPrice target
May 18B of A SecuritiesMaintainedSell$3
Loading…

Technical Analysis

EMBC · as of the Nov 17 close · updated after every close
Moving sideways

The stock sits between its 20 and 50 day averages. It is sitting right on its 200 day average, a level many traders watch. Momentum is fading (RSI 47). The nearest support is the 200 day average at $6.14, and the nearest resistance the swing high (Oct 7) at $6.16.

Short trendNeutral
Long trendBearish
MomentumFading
StretchNormal
VolatilityNormal, 5.1%/day
Key levels
$14.8152 week high+140.8%
$6.4420 day average+4.7%
$6.27Pivot R1+2.0%
$6.16Swing high (Oct 7)+0.2%
$6.15Last close
$6.14200 day average−0.2%
$6.14Pivot−0.2%
$6.03Pivot S1−2.0%
$5.9950 day average−2.6%
$5.78Swing low (Nov 6)−6.0%
$5.08100 day average−17.4%
$2.7752 week low−55.0%
Indicators
RSI (14)47.05Middle of its rangeNeutral
MACD0.07Below its signal lineBearish
Stochastic48.2Middle of its rangeNeutral
ADX (14)18.6No clear trend
Williams %R-63.0Oversold below −80, overbought above −20Neutral
CCI (20)-118.5Oversold below −100, overbought above 100Oversold
Rate of change+1.1%Change over 10 sessionsBullish
ATR (14)$0.31Typical daily range, 5.1% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for EMBC

What happened before

See how EMBC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Earnings in 6 daysSignals right before a report are less reliable. The report can override them.
November seasonalityHow EMBC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How EMBC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in EMBC in the last 90 days.

Loading…

See today’s whale options flow across the market →

EMBC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●139 buying vs 131 selling
  • ▲Held by funds +3.2 pts
  • ▼Funds holding -4
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding321325−1.2%
In funds' top 1021+100.0%
Held by funds92.2%88.9%+3.2 pts
New / increased59 / 8059 / 800.0%
Reduced / sold out73 / 5875 / 72−10.9%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EMBC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EMBC is in one of them and how their past EMBC trades turned out.

EMBC in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered EMBC in an article yet. Here's the latest on the wider market.

EMBC Congress Trades

All congress trades →
Trades, 12 months
4
Buys
1
25%
Sells
2
50%
People
1
Last filed Jul 1
Who traded EMBC · since 2022
Latest 5 filings
$1K – $15KTraded May 15, 2026Filed Jul 1, 2026
$15K – $50KTraded Mar 30, 2026Filed May 14, 2026
$15K – $50KTraded Feb 26, 2026Filed May 14, 2026
$15K – $50KTraded Jan 26, 2026Filed May 14, 2026
$1K – $15KTraded Apr 1, 2022Filed Apr 26, 2022
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$1K – $15KMay 15, 2026Jul 1, 202647 d
Donald J TrumpExecutive branchSell$15K – $50KMar 30, 2026May 14, 202645 d
Donald J TrumpExecutive branchBuy$15K – $50KFeb 26, 2026May 14, 202677 d
Donald J TrumpExecutive branchOther$15K – $50KJan 26, 2026May 14, 2026108 d
Tom ColeR · OKBuy$1K – $15KApr 1, 2022Apr 26, 202225 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Embecta

Embecta is a medical device company focused on helping people with diabetes manage insulin injections. Its main products are pen needles, insulin syringes and safety injection devices, which are designed to work with insulin pens and vials and to help protect users and healthcare workers from needlestick injuries. The company sells to patients, retailers, hospitals, pharmacies and other healthcare providers in many countries. It is based in Parsippany, New Jersey.

Headquarters
Parsippany, NJ